Deutsch English Français

Contact

EP2831111

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP2831111

EP2831111 - ANG2-BINDING MOLECULES [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 24.01.2020 Database last updated on 17.07.2024
Former	The patent has been granted Status updated on 15.02.2019
Former	Grant of patent is intended Status updated on 23.08.2018
Former	Examination is in progress Status updated on 17.11.2017
Most recent event Tooltip	24.01.2020	No opposition filed within time limit	published on 26.02.2020 [2020/09]
Applicant(s)	For all designated states Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim / DE
	[2019/06]
Former [2015/06]	For all designated states Boehringer Ingelheim International GmbH Corporate Patents Binger Strasse 173 55216 Ingelheim Am Rhein / DE
Inventor(s)	01 / BORGES, Eric BOEHRINGER INGELHEIM GMBH Corporate Patents Binger Strasse 173 55216 Ingelheim Am Rhein / DE
	02 / GSCHWIND, Andreas BOEHRINGER INGELHEIM GMBH Corporate Patents Binger Strasse 173 55216 Ingelheim Am Rhein / DE
	03 / OTT, Rene Georg BOEHRINGER INGELHEIM GMBH Corporate Patents Binger Strasse 173 55216 Ingelheim Am Rhein / DE
	04 / BUYSE, Marie-Ange Burg. E. Ronsestraat 23 9820 Merelbeke / BE
	05 / BOUCNEAU, Joachim Elsboslaan 41 9840 De Pinte / BE
	06 / MERCHIERS, Pascal Loopstraat 23 2460 Kasterlee / BE
	07 / DEPLA, Erik Burgstraat 58 9070 Destelbergen / BE
	08 / STEVENAERT, Frederik Kerkemstraat 11 9680 Maarkedal / BE
	[2015/06]
Representative(s)	Weik, Steffen, et al Boehringer Ingelheim GmbH Corporate Patents Binger Strasse 173 55216 Ingelheim am Rhein / DE
	[2019/12]
Former [2015/06]	Weik, Steffen Boehringer Ingelheim GmbH Corporate Patents Binger Strasse 173 55216 Ingelheim am Rhein / DE
Application number, filing date	13718796.9	27.03.2013
	[2019/12]
	WO2013EP56635
Priority number, date	EP20120162615	30.03.2012 Original published format: EP 12162615
	[2015/06]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2013144266
	Date:	03.10.2013
	Language:	EN
	[2013/40]
	Type:	A1 Application with search report
	No.:	EP2831111
	Date:	04.02.2015
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 03.10.2013 takes the place of the publication of the European patent application.
	[2015/06]
	Type:	B1 Patent specification
	No.:	EP2831111
	Date:	20.03.2019
	Language:	EN
	[2019/12]
Search report(s)	International search report - published on:	EP	03.10.2013
Classification	IPC:	C07K16/22, A61K39/395, A61P35/00	[2015/06]
	CPC:	C07K16/22 (EP,IL,US); C07K16/3038 (IL,US); A61K39/3955 (IL,US); A61K45/06 (IL,US); A61P13/12 (EP,IL); A61P27/02 (EP); (+) A61P35/00 (EP); C07K16/3015 (IL,US); C07K16/303 (IL,US); C07K16/3069 (IL,US); C07K2317/33 (EP,IL,US); C07K2317/565 (IL,US); C07K2317/567 (IL,US); C07K2317/569 (EP,IL,US); C07K2317/76 (EP,IL,US); C07K2317/92 (EP,IL,US) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/06]
Extension states	BA	Not yet paid
	ME	Not yet paid
Title	German:	ANG2 BINDENDE MOLEKÜLE	[2018/30]
	English:	ANG2-BINDING MOLECULES	[2015/06]
	French:	MOLÉCULES LIANT ANG2	[2018/30]
	Former [2015/06]	ANG2-BINDENDE MOLEKÜLE
	Former [2015/06]	MOLÉCULES DE LIAISON À ANG2
Entry into regional phase	30.10.2014	National basic fee paid
	30.10.2014	Designation fee(s) paid
	30.10.2014	Examination fee paid
Examination procedure	30.10.2014	Examination requested [2015/06]
	12.06.2015	Amendment by applicant (claims and/or description)
	17.11.2017	Despatch of a communication from the examining division (Time limit: M02)
	12.01.2018	Reply to a communication from the examining division
	24.08.2018	Communication of intention to grant the patent
	18.12.2018	Receipt of the translation of the claim(s)
	03.01.2019	Fee for grant paid
	03.01.2019	Fee for publishing/printing paid
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 17.11.2017
Opposition(s)	02.01.2020	No opposition filed within time limit [2020/09]
Fees paid	Renewal fee
	31.03.2015	Renewal fee patent year 03
	31.03.2016	Renewal fee patent year 04
	31.03.2017	Renewal fee patent year 05
	03.04.2018	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	SM	20.03.2019
	[2019/52]
Cited in	International search	[A]WO2009147248 (ABLYNX NV [BE], et al) [A] 1-18 * the whole document *;
		[Y]WO2010066836 (ABLYNX NV [BE], et al) [Y] 1-18 * the whole document * * in particular * * abstract * * page 1, line 4 - page 8, line 28 * * page 17, line 1 - page 22, line 27 * * page 218, line 1 - page 234, line 7 * * figures 1-17; examples 1-23; claims 1-15; sequences 464-471 *;
		[AD]US2011027286 (THURSTON GAVIN [US], et al) [AD] 1-18 * the whole document *;
		[Y] - WARK K L ET AL, "Latest technologies for the enhancement of antibody affinity", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 58, no. 5-6, doi:10.1016/J.ADDR.2006.01.025, ISSN 0169-409X, (20060807), pages 657 - 670, (20060807), XP024892147 [Y] 1-18 * the whole document * DOI: http://dx.doi.org/10.1016/j.addr.2006.01.025
		[Y] - CARTER P J, "POTENT ANTIBODY THERAPEUTICS BY DESIGN", NATURE REVIEWS. IMMUNOLOGY, NATURE PUBLISHING GROUP, GB, (20060407), vol. 6, doi:10.1038/NRI1837, ISSN 1474-1733, pages 343 - 357, XP007901440 [Y] 1-18 * the whole document * DOI: http://dx.doi.org/10.1038/nri1837
		[A] - REVETS H ET AL, "NANOBODIES AS NOVEL AGENTS FOR CANCER THERAPY", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, (20050101), vol. 5, no. 1, doi:10.1517/14712598.5.1.111, ISSN 1471-2598, pages 111 - 124, XP009076361 [A] 1-18 * the whole document * DOI: http://dx.doi.org/10.1517/14712598.5.1.111
	by applicant	WO9404678
		US5643755
		WO9849185
		US6166185
		WO02056910
		WO03002609
		WO2004041862
		WO2004041863
		WO2004041865
		WO2004041867
		WO2004092215
		WO2005044858
		WO2006004678
		US2006018909
		WO2006040153
		US2006246071
		WO2006122786
		US7205275
		US2008014196
		WO2008020079
		WO2008101985
		US7521053
		US2009191212
		WO2009109635
		US2011027286
		- YANCOPOULOS ET AL., NATURE, (2000), vol. 407, pages 242 - 248
		- AUGUSTIN ET AL., NAT REV MOL CELL BIOL., (200903), vol. 10, no. 3, pages 165 - 77
		- FALC6N ET AL., AM J PATHOL., (200911), vol. 175, no. 5, pages 2159 - 70
		- GOEDE ET AL., BR J CANCER., (20101026), vol. 103, no. 9, pages 1407 - 14
		- PARK ET AL., CHEST., (200707), vol. 132, no. 1, pages 200 - 6
		- HELFRICH ET AL., CLIN CANCER RES., (20090215), vol. 15, no. 4, pages 1384 - 92
		- FOLKMAN ET AL., NATURE, (1989), pages 339 - 58
		- FERRARA ET AL., NAT REV DRUG DISCOV., (200405), vol. 3, no. 5, pages 391 - 400
		- SAMBROOK ET AL., Molecular Cloning: A Laboratory Manual, COLD SPRING HARBOR LABORATORY PRESS, (1989), vol. 1-3
		- HAMERS-CASTERMAN C; ATARHOUCH T; MUYLDERMANS S; ROBINSON G; HAMERS C; SONGA EB; BENDAHMAN N; HAMERS R., "Naturally occurring antibodies devoid of light chains", NATURE, (1993), vol. 363, doi:doi:10.1038/363446a0, pages 446 - 448, XP002535892 DOI: http://dx.doi.org/10.1038/363446a0
		- KABAT ET AL., Sequence of proteins of immunological interest, NIH BETHESDA, MD, PUBLICATION NO. 91
		- RIECHMANN; MUYLDERMANS, J. IMMUNOL. METHODS, (1999), vol. 231, pages 25 - 38
		- WARD ET AL., NATURE, (1989), vol. 341, pages 544 - 546
		- WARD, E.S. ET AL., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli", NATURE, (1989), vol. 341, pages 544 - 546
		- HOLT, L.J. ET AL., "Domain antibodies: proteins for therapy", TRENDS IN BIOTECHNOLOGY, (2003), vol. 21, no. 11, doi:doi:10.1016/j.tibtech.2003.08.007, pages 484 - 490, XP004467495 DOI: http://dx.doi.org/10.1016/j.tibtech.2003.08.007
		- MARKS ET AL., BIOTECHNOLOGY, (1992), vol. 10, pages 779 - 783
		- BARBAS ET AL., PROC. NAT. ACAD. SCI, USA, (1994), vol. 91, pages 3809 - 3813
		- SHIER ET AL., GENE, (1995), vol. 169, pages 147 - 155
		- YELTON ET AL., IMMUNOL., (1995), vol. 155, pages 1994 - 2004
		- JACKSON ET AL., J. IMMUNOL., (1995), vol. 154, no. 7, pages 3310 - 9
		- HAWKINS ET AL., J. MOL. BIOL., (1992), vol. 226, no. 3, pages 889 - 896
		- CHENG Y; KOH GY, "A designed angiopoietin-2 variant, pentameric COMP-Ang2, strongly activates Tie2 receptor and stimulated angiogensis", BIOCHIM BIOPHYS ACTA, (2009), pages 772 - 780
		- DAUGHERTY ET AL., NUCLEIC ACIDS RESEARCH, (1991), vol. 19, no. 9, pages 2471 - 2476
		- NICAISE, PROTEIN SCIENCE, (2004), vol. 13, pages 1882 - 1891
		- Handbook of Therapeutic Antibodies, WILEY, (2007), pages 252 - 255
		- MARTIN, E.W, Remington's Pharmaceutical Sciences, MACK PUBLISHING CO
		- ERICSSON ET AL., ANAL. BIOCHEM., (2006), vol. 357, pages 289 - 298

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 34p